Deoxyribonucleic acid (DNA) at GpC dinucleotide sites (DNA (GpC))

DNA at GpC sites refers to specific dinucleotide sequences within the deoxyribonucleic acid double helix that serve as the primary molecular target for the antineoplastic antibiotic actinomycin D, also known as dactinomycin (PubChem, CID 2019). The interaction is characterized by the intercalation of the drug's planar phenoxazone ring system between adjacent guanine and cytosine bases, while its two cyclic pentapeptide lactones occupy the minor groove of the DNA (Sobell, 1985, PNAS). This high-affinity binding creates a stable DNA-drug complex that physically obstructs the movement of RNA polymerase, leading to the potent inhibition of transcription, particularly of ribosomal RNA (StatPearls, Dactinomycin). By preventing the synthesis of new mRNA and rRNA, the drug effectively halts protein production and induces apoptosis in rapidly proliferating cells. Clinically, targeting these DNA sites is a standard therapeutic approach for treating various pediatric malignancies, including Wilms tumor and rhabdomyosarcoma, as well as certain germ cell tumors (NIH, NCI Drug Dictionary). However, because the target is a fundamental structural component of all genomic DNA, the drug exhibits significant systemic toxicities, most notably bone marrow suppression and potential liver damage.

Other names

GpC dinucleotideGuanine-cytosine DNA sequencesDNA intercalation sitesDactinomycin-DNA complex

Actinomycin D intercalates its phenoxazone ring between adjacent guanine-cytosine (GpC) base pairs in the DNA double helix. This binding is further stabilized by the drug's cyclic pentapeptides which sit in the minor groove, creating a stable complex that sterically hinders the progression of RNA polymerase along the DNA template, thereby inhibiting DNA-directed RNA synthesis (PubMed, PMID 3903744; StatPearls, NBK538191).